89 related articles for article (PubMed ID: 11071240)
21. ErbB2 and fatty acid synthase (FAS) expression in 102 squamous cell carcinomas of the tongue: correlation with clinical outcomes.
Silva SD; Perez DE; Alves FA; Nishimoto IN; Pinto CA; Kowalski LP; Graner E
Oral Oncol; 2008 May; 44(5):484-90. PubMed ID: 17825601
[TBL] [Abstract][Full Text] [Related]
22. Superselective intra-arterial infusion chemotherapy for stage III/IV squamous cell carcinomas of the oral cavity: midterm results.
Ikushima I; Korogi Y; Ishii A; Hirai T; Yamura M; Nishimura R; Baba Y; Yamashita Y; Shinohara M
Eur J Radiol; 2008 Apr; 66(1):7-12. PubMed ID: 17604932
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of cyclin E overexpression in laryngeal squamous cell carcinomas.
Dong Y; Sui L; Tai Y; Sugimoto K; Hirao T; Tokuda M
Clin Cancer Res; 2000 Nov; 6(11):4253-8. PubMed ID: 11106240
[TBL] [Abstract][Full Text] [Related]
24. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
Shukuwa T; Katayama I; Koji T
Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
[TBL] [Abstract][Full Text] [Related]
25. High expression of S-phase kinase-associated protein 2 (Skp2) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation.
Harada K; Supriatno ; Kawaguchi S; Kawashima Y; Itashiki Y; Yoshida H; Sato M
Anticancer Res; 2005; 25(3c):2471-5. PubMed ID: 16080478
[TBL] [Abstract][Full Text] [Related]
26. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer.
Lyshchik A; Higashi T; Hara T; Nakamoto Y; Fujimoto K; Doi R; Imamura M; Saga T; Togashi K
Cancer Invest; 2007; 25(3):154-62. PubMed ID: 17530485
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma.
Micozkadioğlu D; Unal M; Pata YS; Baştürk M; Cinel L
Med Sci Monit; 2008 Jun; 14(6):CR299-304. PubMed ID: 18509272
[TBL] [Abstract][Full Text] [Related]
28. The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer.
Zhu Y; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ
J Urol; 2008 Nov; 180(5):2019-23. PubMed ID: 18801542
[TBL] [Abstract][Full Text] [Related]
29. Cross-reactivity between Candida albicans and oral squamous cell carcinoma revealed by monoclonal antibody C7.
Rodríguez MJ; Schneider J; Moragues MD; Martínez-Conde R; Pontón J; Aguirre JM
Anticancer Res; 2007; 27(5B):3639-43. PubMed ID: 17972529
[TBL] [Abstract][Full Text] [Related]
30. Expression of PCNA, p53, Bax, and Bcl-X in oral poorly differentiated and basaloid squamous cell carcinoma: relationships with prognosis.
Sampaio-Góes FC; Oliveira DT; Dorta RG; Nonogaki S; Landman G; Nishimoto IN; Kowalski LP
Head Neck; 2005 Nov; 27(11):982-9. PubMed ID: 16136583
[TBL] [Abstract][Full Text] [Related]
31. High expression of Jun activation domain-binding protein 1 (Jab1) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation.
Harada K; Kawashima Y; Yoshida H; Sato M
Anticancer Res; 2006; 26(2B):1615-9. PubMed ID: 16619581
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
[TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of Fas expression in oesophageal squamous cell carcinoma.
Chan KW; Lee PY; Lam AK; Law S; Wong J; Srivastava G
J Clin Pathol; 2006 Jan; 59(1):101-4. PubMed ID: 16394289
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma.
Obara S; Yamamoto K; Hosogai N; Yoshimura Y
Oral Oncol; 2005 Mar; 41(3):276-82. PubMed ID: 15743690
[TBL] [Abstract][Full Text] [Related]
35. Treatment results of oral verrucous carcinoma and its biological behavior.
Ogawa A; Fukuta Y; Nakajima T; Kanno SM; Obara A; Nakamura K; Mizuki H; Takeda Y; Satoh M
Oral Oncol; 2004 Sep; 40(8):793-7. PubMed ID: 15288833
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
[TBL] [Abstract][Full Text] [Related]
37. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients.
Myoung H; Kim MJ; Lee JH; Ok YJ; Paeng JY; Yun PY
Int J Oral Maxillofac Surg; 2006 Nov; 35(11):1005-10. PubMed ID: 17018251
[TBL] [Abstract][Full Text] [Related]
38. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
[TBL] [Abstract][Full Text] [Related]
39. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study.
Kawasaki G; Yoshitomi I; Yanamoto S; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Dec; 94(6):717-23. PubMed ID: 12464897
[TBL] [Abstract][Full Text] [Related]
40. Granisetron reduces clinical and histological response to intra-arterial neoadjuvant chemotherapy in oral squamous cell carcinoma.
Shikimori M; Komatsu H; Hashimoto K; Yamashita Y
Int J Oral Maxillofac Surg; 2006 Sep; 35(9):800-2. PubMed ID: 16854561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
